Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience

Severe ADAMTS13 deficiency occurs in 13% to 75% of thrombotic microangiopathies (TMA). In this context, the early identification of a severe, antibody-mediated, ADAMTS13 deficiency may allow to start targeted therapies such as B-lymphocytes-depleting monoclonal antibodies. To date, assays exploring...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PloS one 2010-04, Vol.5 (4), p.e10208-e10208
Hauptverfasser: Coppo, Paul, Schwarzinger, Michael, Buffet, Marc, Wynckel, Alain, Clabault, Karine, Presne, Claire, Poullin, Pascale, Malot, Sandrine, Vanhille, Philippe, Azoulay, Elie, Galicier, Lionel, Lemiale, Virginie, Mira, Jean-Paul, Ridel, Christophe, Rondeau, Eric, Pourrat, Jacques, Girault, Stéphane, Bordessoule, Dominique, Saheb, Samir, Ramakers, Michel, Hamidou, Mohamed, Vernant, Jean-Paul, Guidet, Bertrand, Wolf, Martine, Veyradier, Agnès
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Severe ADAMTS13 deficiency occurs in 13% to 75% of thrombotic microangiopathies (TMA). In this context, the early identification of a severe, antibody-mediated, ADAMTS13 deficiency may allow to start targeted therapies such as B-lymphocytes-depleting monoclonal antibodies. To date, assays exploring ADAMTS13 activity require skill and are limited to only some specialized reference laboratories, given the very low incidence of the disease. To identify clinical features which may allow to predict rapidly an acquired ADAMTS13 deficiency, we performed a cross-sectional analysis of our national registry from 2000 to 2007. The clinical presentation of 160 patients with TMA and acquired ADAMTS13 deficiency was compared with that of 54 patients with detectable ADAMTS13 activity. ADAMTS13 deficiency was associated with more relapses during treatment and with a good renal prognosis. Patients with acquired ADAMTS13 deficiency had platelet count < 30 x 10(9)/L (adjusted odds ratio [OR] 9.1, 95% confidence interval [CI] 3.4-24.2, P
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0010208